Sangamo receives grant to develop ZFP Therapeutic for Beta-thalassemia
The application of its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem cells (HSCs) will be leveraged in the development of potentially curative ZFP Therapeutic. Funds required